Abstract:To discover novel BChE inhibitors, a hierarchical virtual screening protocol followed by biochemical evaluation was applied. The most potent compound 8012-9656 (eqBChE IC50 = 0.18 ± 0.03 μM, hBChE IC50 = 0.32 ± 0.07 μM) was purchased and synthesized. It inhibited BChE in a noncompetitive manner and could occupy the binding pocket forming diverse interactions with the target. 8012-9656 was proven to be safe in vivo and in vitro and showed comparable performance in ameliorating the scopolamine-induced cognition impairment to tacrine. Additionally, treatment with 8012-9656 could almost entirely recover the Aβ1–42 (icv)-impaired cognitive function to the normal level and showed better behavioral performance than donepezil. The evaluation of the Aβ1–42 total amount confirmed its anti-amyloidogenic profile. Moreover, 8012-9656 possessed blood–brain barrier (BBB) penetrating ability, a long T1/2, and low intrinsic clearance. Hence, the novel potential BChE inhibitor 8012-9656 can be considered as a promising lead compound for further investigation of anti-AD agents.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01129?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01129</a>.Basic information and target inhibitory activities of the 13 hit compounds; binding mode with hBChE and alignment of binding mode with donepezil in hAChE of 8012–9656; structural spectrum data of intermediates, final compounds (8012–9656) and tacrine; molecular formula strings of all compounds; everyday body weight of mice in the acute toxicity assay; standard curve of the mouse Aβ1–42 ELISA kit (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01129/suppl_file/jm0c01129_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

The Structural Modification and Biological Evaluation of Tetrahydrothienopyridine Derivatives As Selective BChE Inhibitors.

[Synthesis and AchE Inhibitory Activity of 2-Phenoxy-indan-1-one Derivatives].

Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: Synthesis and biological evaluation as selective BuChE inhibitors

Discovery of New Selective Butyrylcholinesterase (BChE) Inhibitors with Anti-Aβ Aggregation Activity: Structure-Based Virtual Screening, Hit Optimization and Biological Evaluation

Design, Synthesis and Biological Evaluation of Pyrano[2,3-b]-naphthoquinone Derivatives as Acetylcholinesterase Inhibitors

Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease

Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

2-(2-Indolyl-)-4(3h)-quinazolines Derivates As New Inhibitors of AChE: Design, Synthesis, Biological Evaluation and Molecular Modelling

Hydrazide‐Bridged Pyridazines for Cholinesterase Inhibitors: Synthesis, Characterizations, In Silico, and In Vitro Evaluation

6-acetyl-5H-thiazolo[3,2-a]pyrimidine derivatives as the novel acetylcholinesterase inhibitors: design, synthesis, and biological activity.

Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors Against Alzheimer’s Diseases

Synthesis, Biological Activity, X-ray Crystallographic, DFT Calculations and Molecular Dynamics Simulation Studies of 2-Phenylthiazole-1,3,5-triazine Derivatives As Potential Cholinesterase Inhibitors

Design, synthesis and evaluation of N-arylmethylamide derivatives as cholinesterase inhibitors

Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors

Synthesis, biological evaluation and molecular modeling of substituted 2-aminobenzimidazoles as novel inhibitors of acetylcholinesterase and butyrylcholinesterase.

Discovery, Molecular Dynamic Simulation and Biological Evaluation of Structurally Diverse Cholinesterase Inhibitors with New Scaffold Through Shape-Based Pharmacophore Virtual Screening.

Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations.

Discovery of Novel Isoflavone Derivatives As AChE/BuChE Dual-Targeted Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling

Design, Synthesis, and Proof of Concept of Balanced Dual Inhibitors of Butyrylcholinesterase (bche) and Histone Deacetylase 6 (HDAC6) for the Treatment of Alzheimer's Disease.

Design, synthesis, biological evaluation, and docking study of 4-isochromanone hybrids bearing N-benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors (part II).